Sharing International Collaborative Achievements between Institut Pasteur Korea and Pasteur Network

Sharing International Collaborative Achievements
between Institut Pasteur Korea and Pasteur Network


(From left to right) Meehyun Ko from Business Development Team, CEO Byungkwon Lim, CSO Dimitri Lavillette, Dahae Koh from Screening Discovery Platform
Institut Pasteur Korea (IPK) participated in the 2023 Pasteur Network Annual Meeting (PNAM) held at the Institut Pasteur de Tunis (IPT) from November 19 to 21. During the event, IPK strengthened ties with members of the Pasteur Network and diverse foundations including Wellcome, Rockefeller and Grand Challenge Canada.

The PN Annual Meeting (PNAM) was attended by four executives and staff members of Institut Pasteur Korea, including the CEO Mr. Byungkwon Lim and the CSO Dr. Dimitri Lavillette.

PNAM commenced with the opening remarks by Samia Menif, the current  Director General of IPT and its former director general Dr Hechmi Louzir. Dr Amadou Sall, President of the Pasteur Network, Stewart Cole, the President of Pasteur Network Foundation and current President of Institut Pasteur as well as Rebecca F. Grais Executive Director of the Pasteur Network provided messages on expected future actions for the PN. Finally, PNAM has the honor to welcome encouraging remarks from the Pr Ali Mrabet, Minister of Public Health in Tunisia and from Pr Moncef Boukthir, the Minister of Higher Education and Scientific Research of Tunisia.

▶See all programs

In preamble of the PNAM, the IPK CEO, participated in key meetings, including the Board of Directors’ Meeting, as one of the Board member of the Pasteur Network Association and Foundation as well as the Co-Representative for the Asia-Pacific region, and presided over the deliberations on key activities, budgets, financial reports, and other matters of the network.

During PNAM, sessions and roundtable discussions related to global public health were held, focusing on global thematic priorities such as climate-sensitive emerging infectious diseases, the research and development (R&D) and innovation ecosystem, and antimicrobial resistance.

Five sessions were conducted, covering the following themes: Reinforcing epidemic intelligence and preparedness, Supporting the R&D & Innovation ecosystem in LMICS (Low- and Middle-Income Countries), Ensuring equitable collaboration and inclusive voices within the Pasteur Network, and Spotlight on climate and health opportunities.
In particular, young scientists from four regions within the Pasteur Network presented under the theme "Developing our multidisciplinary knowledge communities: Young scientists of the Pasteur Network." Researchers from Canada, Guinea, Laos, and Bulgaria shared insights on building multidisciplinary communities, presented training and education programs, and discussed collaborative approaches.

Additionally, Dr. Stewart Cole, President of the Institut Pasteur and a member of IPK  Board of Directors, presented efforts in the development of new drugs within the Pasteur Network under the theme "Tuberculosis – the forgotten pandemic."

In particular, he introduced the development status of Q203 (Telacebec), the first-in-class drug candidate against MDR- and XDR- TB, developed by the IPK, currently in Phase 2 clinical trials. Additionally, he presented the consortium (ERA4TB) aimed at developing new drugs for tuberculosis.

IPK presented posters highlighting collaborative research conducted jointly with other institutes within the Pasteur Network.

IPK has gained attention for projects, including the drug discovery activities of the International Joint Research Laboratory (PIU, Pasteur International Unit) established in collaboration between IPK and Institut Pasteur targeting ‘Artificial Intelligence for image-based Drug Discovery & Development.’

Additionally, IPK showcased various joint projects conducted in collaboration with the Pasteur Network. These include a project on the Candida auris drug discovery efforts with IPT and IPP, and a project on Dengue virus NS1 tarteged drug screening with IPP and Institut de Chimie des Substances Naturelles CNRS. Both projects benefit from the state of the art IPK’s High-Throughput screening platform.

▲Artificial Intelligence for image-based Drug Discovery & Development (Ai3D)

▲Assay validation & high-throughput screening of Candida auris identifies differential chemical signatures amongst regional clades